Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 301

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 301
---
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                            ($ ’ 000)                                
  Cash Flow Data:                                                                                                    
  Net cash generated from/(used in) operating activities                          497        219,258      (268,599)  
  Net cash (used in)/generated from investing activities                     (96,060)      (291,136)        296,588  
  Net cash (used in)/generated from financing activities                     (30,667)         48,660       (82,763)  
  Net decrease in cash and cash equivalents                                 (126,230)       (23,218)       (54,774)  
  Effect of exchange rate changes                                             (3,401)        (6,471)        (9,490)  
  Cash and cash equivalents at beginning of the year                          283,589        313,278        377,542  
  Cash and cash equivalents at end of the year                                153,958        283,589        313,278  

Net Cash generated from/(used in) Operating Activities

Net cash generated from operating activities was $219.3 million for the year ended December 31, 2023, compared to $0.5 million for the year ended December 31, 2024. The net change of $218.8 million was attributable to a decrease of $63.1 million in net income attributable to HUTCHMED from $100.8 million for the year ended December 31, 2023 to $37.7 million for the year ended December 31, 2024. The net change was also attributable to changes in working capital of $133.3 million where there was an increase in cash from the working capital of $71.1 million for the year ended December 31, 2023 (primarily due to an increase of $119.8 million in deferred revenue mainly from the receipt of the Takeda upfront payment), as compared to a decrease in cash from the working capital of $62.2 million for the year ended December 31, 2024 (primarily due to an increase in accounts receivable of $38.5 million including regulatory approval milestone payments, royalties and sales of goods from Takeda and a decrease in deferred revenue of $26.0 million including the $30.8 million revenue recognized from the Takeda upfront payment received during the year ended December 31, 2023).

For a